NHS Patients

0333 202 0300

Medico Legal

0333 202 3188

Self Pay & PMI

0333 200 2064

Radioligand Therapy

InHealth is proud to offer the UK and World’s first Relocatable Radioligand Therapy (RLT) service – a ground-breaking development in cancer care

Radioligand Therapy (RLT), which is sometimes referred to as Molecular Radiotherapy (MRT), is a uniquely innovative approach to cancer treatment that, while already available in the UK at a very small number of static locations, is expected to play a much more integral role in cancer treatment in the near future.

RLT is a type of therapy that uses radiation to target cancer cells using specific molecules or ligands, and typically supports patients with neuroendocrine tumours and prostate cancer. At InHealth, our existing PET-CT services already support over 20,000 UK cancer patients each year through both mobile and static sites, and what makes this brand new RLT service so unique and exciting is that we offer it through the world’s first relocatable facility.

Not only does this service provide additional capacity to existing sites that offer the care from acute hospitals and static locations, but it can be moved and relocated on a daily basis. This allows us to support patients in new and harder-to-reach locations, providing them with a service that has never before been an option because of geographical constraints.

This new service will support increased access for patients to receive treatments via research, NHS and private pathways across the UK and World.

By combining this new therapy service with InHealth’s existing position as the UK’s largest specialist provider of diagnostic and healthcare solutions, we are proud to confirm our place at the forefront of innovations in therapy-based cancer patient diagnostics and treatment (also known as Theranostics).

If you are a Clinician or part of a healthcare organisation that would like to explore gaining access to this Relocatable RLT service for your healthcare setting and patients, please contact Ralph Toop, Director of Operations – PET-CT & Specialised Services, at radiology@inhealthgroup.com. We can share more information about how InHealth can provide a fully staffed solution through our team of highly trained and experienced RLT staff, to support service delivery.

If you are a patient who requires access to this service, please speak to your GP/Clinician, who will explore your options and who can reach out to InHealth and our new Relocatable RLT service, where appropriate.

Read More Here

CANCER RESEARCH UK

Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours (NETs)

PROSTATE CANCER UK

Behind the headlines lutetium therapy

BRITISH NUCLEAR MEDICINE SOCIETY

The BNMS Molecular Radiotherapy Group

RCR PUBLICATIONS

Review of molecular radiotherapy services in the UK

Radioligand Therapy

InHealth is proud to offer the UK and World’s first Relocatable Radioligand Therapy (RLT) service – a ground-breaking development in cancer care

Radioligand Therapy (RLT), which is sometimes referred to as Molecular Radiotherapy (MRT), is a uniquely innovative approach to cancer treatment that, while already available in the UK at a very small number of static locations, is expected to play a much more integral role in cancer treatment in the near future.

RLT is a type of therapy that uses radiation to target cancer cells using specific molecules or ligands, and typically supports patients with neuroendocrine tumours and prostate cancer. At InHealth, our existing PET-CT service already supports over 20,000 UK cancer patients each year through both mobile and static sites, and what makes this brand new RLT service so unique and exciting is that we offer it through the world’s first relocatable facility.

Not only does this service provide additional capacity to existing sites that offer the care from acute hospitals and static locations, but it can be moved and relocated on a daily basis. This allows us to support patients in new and harder-to-reach locations, providing them with a service that has never before been an option because of geographical constraints.

This new service will support increased access for patients to receive treatments via research, NHS and private pathways across the UK and World.

By combining this new therapy service with InHealth’s existing position as the UK’s largest specialist provider of diagnostic and healthcare solutions, we are proud to confirm our place at the forefront of innovations in therapy-based cancer patient diagnostics and treatment (also known as Theranostics).

If you are a Clinician or part of a healthcare organisation that would like to explore gaining access to this Relocatable RLT service for your healthcare setting and patients, please contact Ralph Toop, Director of Operations – PET-CT & Specialised Services, at radiology@inhealthgroup.com. We can share more information about how InHealth can provide a fully staffed solution through our team of highly trained and experienced RLT staff, to support service delivery.

If you are a patient who requires access to this service, please speak to your GP/Clinician, who will explore your options and who can reach out to InHealth and our new Relocatable RLT service, where appropriate.

Read More Here

CANCER RESEARCH UK

Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours (NETs)

PROSTATE CANCER UK

Behind the headlines lutetium therapy

BRITISH NUCLEAR MEDICINE SOCIETY

The BNMS Molecular Radiotherapy Group

RCR PUBLICATIONS

Review of molecular radiotherapy services in the UK